Clinical trials: Urinary Bladder, Overactive
Overactive Bladder (OAB)
Ease of Use Study of the FemPulse System
The objective of the study is to demonstrate that the FemPulse System can be used as indicated
- Trial name
- NCT06885099
- Testing
- FemPulse System
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- FemPulse Corporation
Overactive Bladder (OAB)
Evaluate the Safety and Efficacy of TRG-200 KIT in Patients With Refractory Overactive Bladder.
This is an open-label, single-center pilot study designed to evaluate the safety, tolerability, and preliminary efficacy of TRG-200 KIT, an intravesical sustained-release oxybutynin formulation, in adult patients with refractory…
- Trial name
- NCT07391878
- Testing
- TRG-200 KIT
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Trigone Pharma Ltd.
Overactive Bladder, Overactive Bladder (OAB)
Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women
The goal of this clinical trial is to learn if a vaginal radiofrequency (RF) device called MORPHEUSV works to treat overactive bladder (OAB) in women. Researchers also want to learn how safe the device is for this indication.
- Conditions
- Overactive Bladder, Overactive Bladder (OAB), Urge Urinary Incontinence, Mixed Urinary Incontinence (Urge-Predominant)
- Trial name
- DENARA (NCT07209397)
- Testing
- Detrusor nerve radiofrequency ablation
- Where
- 9 sites in United States
- Volunteers
- 202 people
- Sponsor
- InMode MD Ltd.
Urologic Diseases, Urodynamics
Modern Urodynamics System Efficacy (MUSE) Study
The goal of this prospective trial is to evaluate the feasibility, efficacy, and safety of the Glean Urodynamics System (GUS) for use in the clinic to collect vesical pressure data in adult males and females with lower urinary…
- Trial name
- MUSE (NCT05959655)
- Testing
- Glean Urodynamics System
- Where
- 5 sites in United States
- Volunteers
- 38 people
- Sponsor
- Bright Uro
Overactive Bladder
Evaluation of Implantable Tibial Neuromodulation Pivotal Study (TITAN 2)
The purpose of this prospective, multicenter study is to assess the safety and efficacy of tibial neuromodulation using the Medtronic Tibial Neuromodulation (TNM) system.
- Trial name
- TITAN 2 (NCT05226286)
- Testing
- Medtronic Implantable Tibial Neuromodulation (TNM) System
- Where
- 29 sites in United States
- Volunteers
- 188 people
- Sponsor
- MedtronicNeuro
Urinary Bladder, Overactive, Spinal Cord Injury
Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy
The aim of this study is to continue following participants who have received EG110A during five years to know how it is tolerated in humans, any side-effects it may cause and what might be an effective dose over five years.
- Trial name
- NCT07227285
- Testing
- Urodynamics, EG110A, Patient-reported Outcome
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Cyllene Therapeutics
Overactive Bladder, Urge Incontinence
Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence
This trial is a prospective, multicenter, single-arm study of the safety and effectiveness of eCoinTM tibial nerve stimulation in subjects having overactive bladder (OAB) with urgency urinary incontinence (UUI).
- Conditions
- Overactive Bladder, Urge Incontinence, Incontinence, Urinary, Urinary Urge Incontinence
- Trial name
- NCT03556891
- Testing
- eCoin Tibial Nerve Stimulation
- Where
- 15 sites in United States
- Volunteers
- 133 people
- Sponsor
- Valencia Technologies Corporation
Urinary Retention, Urinary Urge Incontinence
Axonics SacRal NeuromodulaTIon System RegisTRY Study
To assess the post-market clinical outcomes with use of the Axonics Sacral Neuromodulation System(s).
- Conditions
- Urinary Retention, Urinary Urge Incontinence, Urgency-Frequency, Fecal Incontinence
- Trial name
- ARTISTRY (NCT05064384)
- Where
- 27 sites in United States, Canada
- Volunteers
- 272 people
- Sponsor
- Axonics, Inc.
Overactive Bladder Syndrome, Urinary Urge Incontinence
Cycling Study With the Axonics System
A prospective, multi-center, study comparing continuous sacral neuromodulation (SNM) stimulation to daily cyclic stimulation of 2 hours "on" and 22 hours "off" using the Axonics System.
- Conditions
- Overactive Bladder Syndrome, Urinary Urge Incontinence, Sacral Neuromodulation
- Trial name
- NCT05543382
- Testing
- Axonics System
- Where
- 6 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Axonics, Inc.
Overactive Bladder, Urinary Frequency
FREEOAB Study for Overactive Bladder
This is a prospective, multicenter study that was conducted to evaluate the safety and efficacy of a novel, closed-loop, continuous-sensing wearable neuromodulation system for Overactive Bladder symptom control.
- Conditions
- Overactive Bladder, Urinary Frequency, Urinary Incontinence, Urge, Urinary Urgency
- Trial name
- NCT04547920
- Testing
- Wearable Bladder Modulation System
- Where
- 9 sites in United States
- Volunteers
- 96 people
- Sponsor
- Avation Medical, Inc.
Overactive Bladder
Evaluation of the Tensi+ Device for the Treatment of Overactive Bladder
Tensi+ (Stimuli Technology, Boulogne Billancourt, France) is a newly released, medical transcutaneous-posterior tibial nerve stimulation (TC-pTNS) device marketed for overactive bladder (OAB) management.
- Trial name
- NCT06847789
- Testing
- Tensi+
- Where
- France
- Volunteers
- 79 people
- Sponsor
- Stimuli Technology
Detrusor Underactivity, Overactive Bladder
Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder.
The purpose of this study is to evaluate the efficacy and safety of TAC-302 in detrusor underactivity patients with overactive bladder.
- Trial name
- NCT03175029
- Testing
- TAC-302
- Where
- Japan
- Volunteers
- 195 people
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
Overactive Bladder, Fecal Incontinence
InterStim Micro Post Market Clinical Follow-up Study (ELITE)
Post-market clinical follow-up for continued assessment of safety and performance to confirm long-term outcomes of the InterStim Micro System for sacral neuromodulation.
- Conditions
- Overactive Bladder, Fecal Incontinence, Non-obstructive Urinary Retention
- Trial name
- ELITE (NCT04506866)
- Testing
- InterStim Micro
- Where
- 24 sites in United States, Canada and 4 more
- Volunteers
- 148 people
- Sponsor
- MedtronicNeuro
Overactive Bladder
Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)
This study will evaluate the treatment satisfaction, discontinuation, reasons for discontinuation, quality of life, healthcare resource utilization, and safety with Vibegron for the treatment of OAB in the context of real-world…
- Trial name
- NCT05067478
- Testing
- Vibegron
- Where
- 64 sites in United States
- Volunteers
- 403 people
- Sponsor
- Urovant Sciences GmbH
Detrusor Overactivity, Overactive Bladder
Study of 2 Doses of Solifenacin Succinate in Female Subjects With Overactive Bladder.
The purpose is to see if solifenacin has any effect on bladder wall thickness and urine inflammatory marker measurements after 12 weeks of treatment.
- Trial name
- SHRINK (NCT01093534)
- Testing
- solifenacin
- Where
- 79 sites in United States, Austria and 18 more
- Volunteers
- 547 people
- Sponsor
- Astellas Pharma Inc
Overactive Bladder (OAB)
Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
The purpose of this study was to assess the efficacy, safety and tolerability of mirabegron versus placebo in the treatment of older adult subjects with OAB.
- Trial name
- PILLAR (NCT02216214)
- Testing
- Mirabegron
- Where
- 120 sites in United States, Canada
- Volunteers
- 888 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Urinary Bladder, Overactive
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
The study is intended to test efficacy, safety and tolerability of two doses of once daily (qd) Mirabegron against placebo to treat patients with symptoms of overactive bladder.
- Trial name
- CAPRICORN (NCT00912964)
- Testing
- Mirabegron
- Where
- 151 sites in United States, Canada and 9 more
- Volunteers
- 2,030 people
- Sponsor
- Astellas Pharma Inc
Urologic Diseases, Urinary Bladder, Overactive
A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.
The purpose of the study was to assess the efficacy, safety and tolerability of mirabegron 50 mg versus (vs) solifenacin 5 mg in the treatment of patients with OAB who were dissatisfied with their treatment due to lack of…
- Conditions
- Urologic Diseases, Urinary Bladder, Overactive, Urinary Bladder Diseases
- Trial name
- BEYOND (NCT01638000)
- Testing
- Mirabegron, Solifenacin succinate
- Where
- 217 sites in Armenia, Austria and 31 more
- Volunteers
- 1,887 people
- Sponsor
- Astellas Pharma Europe Ltd.
Urinary Bladder, Overactive
A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
The study is intended to test the efficacy, safety and tolerability of two doses of mirabegron against placebo to treat patients with symptoms of overactive bladder
- Trial name
- ARIES (NCT00662909)
- Testing
- Mirabegron
- Where
- 125 sites in United States, Canada
- Volunteers
- 2,149 people
- Sponsor
- Astellas Pharma Inc
Urinary Bladder, Overactive
Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
The study is intended to test the safety, tolerability, efficacy of two doses of long term once daily (qd) treatment of Mirabegron in patients with symptoms of overactive bladder and secondly to compare these with active…
- Trial name
- TAURUS (NCT00688688)
- Testing
- Mirabegron, Tolterodine
- Where
- 308 sites in United States, Australia and 28 more
- Volunteers
- 2,792 people
- Sponsor
- Astellas Pharma Inc